For instance, HDAC6 inhibitors have been demonstrated to enhance the sensitivity of cancer cells to various chemotherapeutic agents such as temozolomide [37], gemcitabine [38,39], oxaliplatin [38], eribulin [40], WEE1 inhibitor adavosertib [41], 5-FU [42], and imatinib [43]. This evidence concerns the gene HDAC6 and cancer.